Logo image
S0953 GLP-1 Receptor Agonist Use Is Associated With Reduced Early Progression and Endoscopic Intervention in Barrett’s Esophagus: A Propensity-Matched Real-World Analysis
Abstract   Peer reviewed

S0953 GLP-1 Receptor Agonist Use Is Associated With Reduced Early Progression and Endoscopic Intervention in Barrett’s Esophagus: A Propensity-Matched Real-World Analysis

Faiza Khan, Ishtiaq Ahmad, Muhammad Usman Haider, Muhammad Furqan, Abdullah Sohail, Zhexiang He, Muhammad Tayyab Tahir, Hasan Ilyas, Ali Mohsin, Daniah Rizwan, …
The American journal of gastroenterology, Vol.121(10S1), pp.S206-S207
10/01/2026
DOI: 10.14309/01.ajg.0001213064.09901.7b

View Online

Abstract

Introduction: Barrett’s esophagus (BE) is a premalignant condition associated with progression to dysplasia and esophageal adenocarcinoma (EAC). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) possess anti-inflammatory and metabolic effects that may influence neoplastic progression; however, their impact on BE outcomes remains poorly characterized. We evaluated the association between GLP-1RA use and progression-related outcomes in patients with BE. Methods: We performed a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Adults with non-dysplastic BE were identified using ICD-10 coding. Patients exposed to GLP-1RAs (semaglutide, tirzepatide, liraglutide, dulaglutide, or exenatide) were compared with patients without GLP-1RA exposure. Cohorts were matched 1:1 for demographics, obesity, type 2 diabetes mellitus, gastroesophageal reflux disease, hiatal hernia, smoking, alcohol use disorder, hypertension, hyperlipidemia, and medication use. Outcomes included overall dysplasia progression, low-grade dysplasia (LGD), high-grade dysplasia (HGD), esophageal adenocarcinoma, and endoscopic ablation at 1-, 3-, and 5-year follow-up. Results: After propensity matching, 27,811 patients were included in each cohort. At 1 year, GLP-1RA use was associated with lower risk of overall dysplasia progression (HR 0.77, 95% CI 0.69–0.86, P < 0.001), esophageal adenocarcinoma (HR 0.66, 95% CI 0.50–0.87, P < 0.001), LGD (HR 0.55, 95% CI 0.44–0.69, P = 0.001), HGD (HR 0.72, 95% CI 0.54–0.97, P = 0.037) and endoscopic ablation (HR 0.24, 95% CI 0.18–0.31, P < 0.001). At 3 years, reductions in overall dysplasia progression and esophageal adenocarcinoma were attenuated and no longer statistically significant; however, reduced ablation risk persisted (HR 0.37, 95% CI 0.31–0.45, P < 0.001). LGD remained modestly reduced (HR 0.82, 95% CI 0.69–0.97, P = 0.021). At 5 years, no significant differences were observed in overall dysplasia progression, HGD, or esophageal adenocarcinoma. Reduced endoscopic ablation rates remained significant (HR 0.42, 95% CI 0.36–0.50, P < 0.001). Conclusion: GLP-1RA use in patients with Barrett’s esophagus was associated with reduced short-term dysplastic progression and lower endoscopic intervention requirements, with attenuation of effect over longer follow-up. Persistent reductions in ablation-related outcomes suggest a potential role for GLP-1RAs in modifying early disease progression in BE. Prospective studies are needed to further evaluate these associations.
Endoscopy Esophageal Cancer Ablation GLP-1 receptor agonists

Details

Metrics

1 Record Views
Logo image